Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. - Wikidata - wikimedia - TriplyDB

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q38917883

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation Molecular profiling of biliary tract cancer: a target rich disease Cholangiocarcinoma: Current Knowledge and New Developments Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers New Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement.Cholangiocellular Carcinoma.FGFR-targeted therapeutics for the treatment of breast cancer.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma.Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Advances and challenges in targeting FGFR signalling in cancer.Emerging molecular therapeutic targets for cholangiocarcinoma.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Current biologics for treatment of biliary tract cancers.Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.Human hepatic organoids for the analysis of human genetic diseases.Cholangiocarcinoma, gone without the Wnt?Consensus conference on hilar cholangiocarcinoma.Circulating tumor cells and cholangiocarcinoma.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.Cholangiocarcinoma - evolving concepts and therapeutic strategies.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.

P2860

Q26751224-10EDA27D-456A-4875-A93B-C92A162C2C59 Q26751655-EC277010-18C3-4F4D-8111-FB22ABB4C6C3 Q27322795-72B2FC53-195A-4F0C-93E2-711B50A2F070 Q28072275-5B3E8A72-65F9-47CC-B0CE-70C51F21B9BC Q28076098-0C2C40E9-A02D-432A-9059-2B8575EA9BF6 Q32173000-9C0D649E-B10C-4125-A6DC-B8A7846A99B0 Q33688755-86056F21-EA94-4019-AEC5-9A3BB2792562 Q33763540-AE35DE7E-28C2-4DC5-90CE-5CEA63F54E54 Q36113790-A6464EC8-D6CB-4B93-B880-8D37809329A3 Q36884411-84869D7C-300F-4FCE-A75B-931929833596 Q36905641-303AB5DF-7238-4625-9076-C2E07371B35D Q36983860-47030BFD-3F6F-4ED6-B8D9-C4BA4169CF7B Q37295744-0433720E-6979-4A82-B786-1C3ECEF3595F Q37631655-D6B28967-3A9B-4291-8E5C-DEC08D582F62 Q38619219-4725931C-B4FE-4AB9-B1A8-3D4D4D308920 Q38642455-14116F4E-402A-4397-9595-CD245FDBFCD7 Q38646960-9B482C90-D5E0-4708-986E-41461C56F38A Q38714000-C9B84629-D582-4BE9-9F67-3C07B8749141 Q38746546-C934FD6B-3CF6-4268-91C2-67B8D82382D4 Q38766035-336CAEB1-B289-4FDB-B5B9-EE61723CFF56 Q38776411-4A490353-61E2-4DF6-A27E-1F0C4F486E77 Q38812588-45EC99E2-F4F5-484D-B196-4E1CE60EAB64 Q39022105-1DD6AB74-BE16-4B3D-B787-A146699EF873 Q39120148-2508E9A3-A974-4EB1-AAB3-7EFFA1DDE6E4 Q39183442-C3BB304E-7D66-48BB-9D82-C7CA5D8B88E0 Q39227356-33B7A6BC-650E-48A2-BADD-6157FDB1F311 Q39289707-57589E3E-B566-4C6E-A0DE-02A9F377A764 Q39453572-25CE6775-43AC-4538-8DA7-DF5C24A6B9D3 Q39673531-83B20CB2-EEE3-49BB-8940-D752126D6D24 Q40633762-0A0CB17E-7794-4144-B1F5-0B837A709E50 Q41670809-36DB5DE9-E97C-4971-AC82-6C88195FF85C Q41670848-AD577F4D-F30A-4E89-BE8E-53A721965C4E Q42329118-C7E985A6-EDC3-4131-B431-57F18771318F Q42367643-31D53BE4-BDE0-4D1E-9027-77F6C0B016B1 Q42394127-6B0FF725-CC10-401B-A4C0-90BF46A2543E Q42424903-F64BC1E2-4CD4-4299-AB75-30303123FE3A Q44557002-2E701419-2A03-43D4-889A-95ACBA953AE1 Q44643445-ADA0656F-F1C1-4C28-BBC1-9F2C8112DA90 Q46087686-47C350EE-A2E6-48E0-841F-A380C15729BE Q47429093-4C4681AA-A19C-4017-8540-3965781A6EE6

P2860

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q38917883

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Massive parallel sequencing un ...... trahepatic cholangiocarcinoma.

@en

type

label

Massive parallel sequencing un ...... trahepatic cholangiocarcinoma.

@en

prefLabel

Massive parallel sequencing un ...... trahepatic cholangiocarcinoma.

@en

P1433

Q38917883-9C8EB4C7-D536-4616-A3A6-19F1759A4BA1

P1476

Q38917883-40F37342-4E08-4823-9EC2-58FCDDCA82E5

P2093

Q38917883-066F4724-BDD9-4685-AFF9-502598006A92

Q38917883-14E9D0D9-DA92-4E41-8AFA-AF11B5DA933A

Q38917883-49966ACA-6751-4C3B-9D0C-1CB6375E25BE

Q38917883-52AC7B82-80D8-477F-9737-9EC0B7720621

Q38917883-561F8E8C-95FF-4145-9D58-B342C0FF44E1

Q38917883-7E2ADAF0-B1F7-444B-9703-8E1F86EFA667

Q38917883-81ECF22D-7DCA-44C8-A7D1-853B8B44DBD0

Q38917883-875F1531-88F8-427E-A5CB-DCB367AA52AD

Q38917883-9A5B763D-008B-41F4-BA2F-05E19716805D

Q38917883-9C0543C2-CBFA-4CC9-9F11-0DD25A2CB63D

P2888

Q38917883-5A73438D-169F-466D-8264-C3701E6C3946

P304

Q38917883-6077E19E-79B3-4F01-B61F-A34A3BB6ECD2

P31

Q38917883-54F5B35D-D8D3-46E6-A364-7036A87ECF8C

P356

Q38917883-6D426733-0F76-41D8-9E61-6F918AF30EA9

P407

Q38917883-711742B0-1342-4303-81E0-A20271FF26C5

P478

Q38917883-81D963C9-1BC5-40EC-9C5B-41AA5B463A00

P50

Q38917883-1DA417F5-B57C-4833-8B59-9C62AF66BB09

Q38917883-464F8873-77DC-4614-AE5A-85059FC8D5E3

Q38917883-A3629B27-5EBC-4086-8E3F-C0528C99AEEA

Q38917883-DE31F917-9890-42FC-84CC-DB2A9EB57DAB

P577

Q38917883-26BA38DD-98A2-4217-8369-6C7DD6528176

P6179

Q38917883-1E11C72F-B051-4368-9B14-C664C92843CE

P698

Q38917883-84C58265-624E-4A51-AB46-9580CF23C44B

P921

Q38917883-7F03291C-7293-4570-ADCD-6B325841FF17

P356

P1433

Nature Communications

P1476

Massive parallel sequencing un ...... trahepatic cholangiocarcinoma.

@en

P2093

Bojan Losic

http://www.w3.org/2001/XMLSchema#string

Carlos Cordon-Cardo

http://www.w3.org/2001/XMLSchema#string

Daniela Sia

http://www.w3.org/2001/XMLSchema#string

Dennis Bonal

http://www.w3.org/2001/XMLSchema#string

Eric Schadt

http://www.w3.org/2001/XMLSchema#string

Helena Cornella

http://www.w3.org/2001/XMLSchema#string

Josep Fuster

http://www.w3.org/2001/XMLSchema#string

Kate Revill

http://www.w3.org/2001/XMLSchema#string

Ke Hao

http://www.w3.org/2001/XMLSchema#string

Laia Cabellos

http://www.w3.org/2001/XMLSchema#string

P2888

P304

6087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS7087

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Josep M. Llovet

Vincenzo Mazzaferro

P577

2015-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022244232

http://www.w3.org/2001/XMLSchema#string

P698

25608663

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma